(NASDAQ: CGC) Canopy Growth's forecast annual revenue growth rate of 40.46% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.91%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Canopy Growth's revenue in 2026 is $201,731,159.On average, 7 Wall Street analysts forecast CGC's revenue for 2026 to be $108,541,041,617, with the lowest CGC revenue forecast at $102,499,018,099, and the highest CGC revenue forecast at $113,275,660,421. On average, 6 Wall Street analysts forecast CGC's revenue for 2027 to be $116,502,607,315, with the lowest CGC revenue forecast at $109,610,392,871, and the highest CGC revenue forecast at $125,405,050,972.
In 2028, CGC is forecast to generate $238,011,894,530 in revenue, with the lowest revenue forecast at $117,349,019,615 and the highest revenue forecast at $364,293,586,813.